Research Papers:
Peroxiredoxin 2 is associated with colorectal cancer progression and poor survival of patients
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1778 views | HTML 2293 views | ?
Abstract
LingLong Peng1,*, Rong Wang1,*, JingKun Shang1, YongFu Xiong1, ZhongXue Fu1
1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400014, China
*These authors contributed equally to this work
Correspondence to:
ZhongXue Fu, email: [email protected]
Keywords: colorectal cancer, peroxiredoxin 2, antioxidant enzyme, prognosis
Received: November 14, 2016 Accepted: January 10, 2017 Published: January 24, 2017
ABSTRACT
The present study was to investigate the clinical significance of peroxiredoxin 2 (PRDX2), an oncoenzyme, in the development and progression of colorectal cancer(CRC).We found levels of PRDX2 mRNA and protein were higher in CRC cell lines than in normal human colonic epithelial cells. PRDX2 expression was significantly up-regulated in CRC lesions compared with that in the adjacent noncancerous tissues. CRC tissues from 148 of 226 (65.5%) patients revealed high level of PRDX2 protein expression in contrast to only 13 of 226 (5.8%) PRDX2 strong staining cases in the adjacent noncancerous tissues. Increased expression of PRDX2 protein was significantly associated with poor tumor differentiation (p = 0.001), advanced local invasion (p = 0.046), increased lymph node metastasis (p = 0.008), and advanced TNM stage (p = 0.020). Patients with higher PRDX2 expression had a significantly shorter disease-free survival and worse disease-specific survival than those with low expression. Importantly, PRDX2 up-regulation was an independent prognostic indicator for stage I–III, early stage (stage I-II) and advanced stage (stage III) patients. In conclusion, our findings suggest PRDX2 up-regulation correlates with tumor progression and could serve as a useful marker for the prognosis of CRC.
![Creative Commons License](/images/80x15.png)
PII: 14801